Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Mar 05, 2026
|
DiaMedica Secures Health Canada Approval to Advance Phase 2 Preeclampsia Trial
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT is a gene therapy-focused biotech company developing therapeutic candidates using its proprietary vector platform (lead programs 4D-150 and 4D-710).
|
$417.05M |
$8.62
-3.47%
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Lead programs are oral small-molecule therapeutics targeting NI&I indications.
|
$416.70M |
$13.80
-7.13%
|
|
CYBN
Cybin Inc.
Company's pipeline focuses on neuropsychiatric drug development (MDD, GAD) with CYB003/CYB004.
|
$413.12M |
$8.30
+1.53%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$409.41M |
$17.65
+2.32%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Antibody Discovery Platform reflects the antibody-focused tools and services offered.
|
$405.35M |
$6.85
+2.39%
|
|
DMAC
DiaMedica Therapeutics Inc.
DMAC's lead DM199 is a peptide/protein-based therapeutic (recombinant KLK1) aimed at treating AIS and PE.
|
$401.62M |
$7.58
-2.51%
|
|
IMMP
Immutep Limited
Immutep is focused on immunology therapeutics, including LAG-3 modulation for cancer and autoimmune diseases.
|
$398.69M |
$2.75
+0.92%
|
|
AVIR
Atea Pharmaceuticals, Inc.
Atea's lead program comprises antiviral small-molecule therapeutics targeting HCV.
|
$395.20M |
$5.29
+6.33%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$394.87M |
$30.45
-4.12%
|
|
AURA
Aura Biosciences, Inc.
Aura's lead oncology program bel-sar is a cancer therapy, targeting solid tumors and advancing in Phase 3.
|
$393.22M |
$6.16
-2.69%
|
|
CATX
Perspective Therapeutics, Inc.
Company directly develops and provides radiopharmaceuticals using alpha-emitting Lead-212 for targeted cancer therapy and diagnostic imaging via 203Pb in a theranostic approach.
|
$391.37M |
$5.11
-3.04%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Company is focused on AAV-based gene therapies (LX2006, LX2020) delivering therapeutic genes — direct Gene Therapy business.
|
$390.97M |
$6.76
-6.63%
|
|
BCYC
Bicycle Therapeutics plc
Company's core focus is oncology with Bicycle Molecule platform and multiple lead oncology programs.
|
$390.20M |
$5.35
-4.97%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
Company operates oncology-focused biotechnology with immunotherapy assets.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
iTeos Therapeutics is a biotech company focused on oncology, developing cancer immunotherapies.
|
$388.48M |
$10.15
|
|
MNPR
Monopar Therapeutics Inc.
MNPR is pursuing oncology-focused assets (MNPR-101 radiopharmaceuticals) and monoclonal antibody–based therapies, aligning with Biotech - Oncology.
|
$380.87M |
$56.59
-8.33%
|
|
ALT
Altimmune, Inc.
Pemvidutide is a peptide therapeutic developed by Altimmune (GLP-1/glucagon dual receptor agonist); directly matches the 'Peptide Therapeutics' investable theme.
|
$376.86M |
$3.50
-18.03%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$370.02M |
$7.32
+0.48%
|
|
BNTC
Benitec Biopharma Inc.
BB-301 is an AAV-based gene therapy leveraging gene silencing and wildtype replacement, aligning with Gene Therapy.
|
$369.44M |
$10.66
-2.29%
|
|
LENZ
LENZ Therapeutics, Inc.
VIZZ is an aceclidine-based eye drop marketed as an ophthalmic drug for presbyopia.
|
$367.36M |
$12.86
-0.89%
|
|
ORGO
Organogenesis Holdings Inc.
ReNu knee osteoarthritis program is a cell therapy (biotech) product, aligning with Biotech - Cell Therapy.
|
$364.24M |
$2.89
+0.70%
|
|
EOLS
Evolus, Inc.
Evolus directly produces botulinum toxin type A product (Jeuveau) used for cosmetic neuromodulation, a core injectable aesthetic treatment.
|
$362.34M |
$5.67
+1.52%
|
|
VSTM
Verastem, Inc.
Company is a oncology-focused biotech developing and commercializing cancer therapeutics.
|
$357.58M |
$6.17
+6.11%
|
|
KYTX
Kyverna Therapeutics, Inc.
KYTX's lead and pipeline CAR-T products (KYV-101, KYV-102, KYV-201) are autologous/allogeneic CD19 CAR-T cell therapies, a direct cell therapy product category.
|
$351.59M |
$7.80
-4.06%
|
|
NGNE
Neurogene Inc.
NGNE directly develops gene therapy candidates (NGN-401) and uses a gene therapy platform, matching Biotech - Gene Therapy.
|
$341.24M |
$22.13
-7.44%
|
|
ACRS
Aclaris Therapeutics, Inc.
Company's focus is on immuno-inflammatory diseases, aligning with Immunology Therapeutics.
|
$335.87M |
$3.11
+0.32%
|
|
AKBA
Akebia Therapeutics, Inc.
Vafseo (vadadustat) is Akebia's core product, an oral small-molecule therapeutic (HIF-PHI) for CKD anemia, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$331.71M |
$1.18
-5.60%
|
|
NWBO
Northwest Biotherapeutics, Inc.
DCVax is a dendritic cell-based autologous cell therapy platform, matching Biotech - Cell Therapy.
|
$329.08M |
$0.23
|
Showing page 12 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
